European Congress of Pathology (ECP)

Roche symposia

In-booth talks 

B-cell lymphomas can represent a diagnostic challenge due to significant overlap in clinical and morphologic features with reactive lymphoid proliferations, and traditional methods of determining clonality are limited by sub-optimal sensitivity and/or cumbersome workflows. The ultra-sensitive VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay for light chain restriction will be discussed, with descriptive cases illustrating its utility.

Dr Teresa Marafioti, Professor, University College London

Dr Marta Canamero, Medical Affairs Lead, Roche Diagnostics

Moderator: Bowdoin Su, Medical Affairs Lead, Roche Diagnostics

In this precision pathology symposium we delve into key challenges and opportunities within the biomarker testing pathway. Leading pathologists will unveil innovative solutions they've successfully implemented in their laboratories, enhancing both diagnostic precision and operational efficiency. Through interactive sessions including roundtable discussions and best practice sharing, attendees will gain invaluable insights to inspire advancements in their own practice.

Introduction: Testing pathway and patient leakage points
Pr Angelo Dei Tos, Professor of Pathology at Padua University Hospital (AOUP), Italy

Increasing identification of patients with actionable target
Pr Deniz Nart, Professor of Pathology at Ege University (EU) Hospital, Turkey

Optimising the workflow to reduce failure rates
Pr Sylvie Lantuejoul, Centre Léon Bérard, France

Implementation of one NGS flow to reduce turnaround time
Pr Isabelle Vanden Bempt, Clinical Biologist at UZ Leuven, Belgium

Pr Angelo Dei Tos will chair the session

This session will highlight the history and current landscape of biomarker testing in ovarian cancer (OC) and how these markers have transformed therapy options for ovarian cancer patients. The session will highlight the newest biomarker, folate receptor alpha (FRɑ), and how identifying patients eligible for FRɑ-targeted therapy using the FDA approved VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay has shaped the treatment landscape for patients with platinum-resistant OC. The session will feature oncologist and pathologist panel speakers to give their perspectives on the ovarian cancer patient journey and incorporation of IHC FRɑ testing in this disease and will conclude with a discussion around best practices for implementing FRɑ testing for OC patients in EU countries and key considerations for both pathologists and oncologists.

Dr Michelle Shiller, Medical Director Cancer Genetics, Baylor Sammons Cancer Center and National Medical Director, Genomics and Molecular Pathology Services, PathGroup, US

Dr Domenica Lorusso, Professor of Obstetrics and Gynaecology, Humanitas University and Director, Medical Gynaecology Oncology Unit, Humanitas San Pio X Hospital, Italy

Dr Megan Dumas, Global Medical Affairs Lead, Roche Diagnostics, will chair the session